The value of specific reversal agents in stroke management

Reversal agents prior to IVT in patients taking DOACsПодробнее

SOP for idarucizumab application in stroke patients taking dabigatranПодробнее

Reversal agents for the management of oral anticoagulant-associated ICHПодробнее

'CODE ICH: Time for urgency in intracerebral haemorrhage' - Professor Craig AndersonПодробнее

Updates in Anticoagulation 2015 videoПодробнее

WSA/ESO Joint Webinar - Key Highlights from the European Stroke Organisation Congress 2024Подробнее

Idarucizumab reversal of dabigatran in acute ischemic stroke and intracranial hemorrhageПодробнее

Safe and Effective Use of New Oral AnticoagulantsПодробнее

Anticoagulation reversal prior to thrombolysisПодробнее

Overview of Intracerebral Hemorrhage (ICH) — Causes, BP Management, Anticoagulation ReversalПодробнее

Acute Management of Ischemic StrokeПодробнее

AINeuroCare - Stroke and DOACsПодробнее

STROKE CONCLAVE 2022 - International Stroke UpdateПодробнее

Reversing DOACS: Providing Answers to What, Where and HowПодробнее

Calabadions: New Broad-Spectrum Agents to Reverse Neuromuscular Blockade and AnesthesiaПодробнее

Oct. 2024 PEP Talk: Anticoagulation and Reversal AgentsПодробнее

Acute Ischemic Stroke | EM:Prep 2023 LLSA ReviewПодробнее

Updates in Acute Stroke Treatment & PreventionПодробнее

MyEMCert Key Advance | Anticoagulant Reversal StrategiesПодробнее

NOACs fact and fictionПодробнее

Afib: NOAC Antidotes: 2016 CCS Atrial Fibrillation GuidelinesПодробнее